EGR1 c.1003del ;(p.E335Nfs*197)

Variant ID: 5-137803141-CG-C

NM_001964.2(EGR1):c.1003del;(p.E335Nfs*197)

This variant was identified in 2 publications

View GRCh38 version.




Publications:


Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.

Npj Genomic Medicine
Koster, R R; Brandão, R D RD; Tserpelis, D D; van Roozendaal, C E P CEP; van Oosterhoud, C N CN; Claes, K B M KBM; Paulussen, A D C ADC; Sinnema, M M; Vreeburg, M M; van der Schoot, V V; Stumpel, C T R M CTRM; Broen, M P G MPG; Spruijt, L L; Jongmans, M C J MCJ; Lesnik Oberstein, S A J SAJ; Plomp, A S AS; Misra-Isrie, M M; Duijkers, F A FA; Louwers, M J MJ; Szklarczyk, R R; Derks, K W J KWJ; Brunner, H G HG; van den Wijngaard, A A; van Geel, M M; Blok, M J MJ
Publication Date: 2021-11-15

Variant appearance in text: 225: 1003del
PubMed Link: 34782607
Variant Present in the following documents:
  • 41525_2021_258_MOESM2_ESM.xlsx, sheet 1
View BVdb publication page



EMQN best practice guidelines for molecular genetic testing and reporting of 21-hydroxylase deficiency.

European Journal Of Human Genetics : Ejhg
Baumgartner-Parzer, Sabina S; Witsch-Baumgartner, Martina M; Hoeppner, Wolfgang W
Publication Date: 2020-10

Variant appearance in text: 225: 1003del
PubMed Link: 32616876
Variant Present in the following documents:
  • Main text
  • 41431_2020_Article_653.pdf
View BVdb publication page